中国经济网北京8月27日讯天域生物（603717）(603717.SH)昨晚披露2025年度向特定对象发行A股股票预案，本次向特定对象发行股票的发 行对象为公司实际控制人罗卫国控制的导云资产。本次发行对象以现金方式认购本次发行的股票。 经双方协商一致，发行价格确定为6.55元/股，不低于定价基准日前20个交易日公司股票交易均价的80%。 本次向特定对象发行股票的种类为境内上市的人民币普通股(A股)，每股面值为人民币1.00元。本次向特定对象发行的股票在锁定期届满 后，在上海证券交易所上市交易。本次向特定对象发行A股股票数量确定为不超过71,028,297股(含本数)，发行股票数量的上限不超过本次发 行前公司总股本的30%。 本次募集资金总额不超过人民币46,523.53万元(含本数)，募集资金在扣除相关发行费用后将全部用于补充流动资金和偿还债务。 本次发行前，罗卫国持有公司12.84%股权，系公司实际控制人。本次认购对象为实际控制人罗卫国控制的导云资产，按本次股票发行上限 计算，发行完成后，罗卫国将控制公司29.98%股份表决权，依然为公司实际控制人，本次发行不会导致公司控制权发生变化。 罗卫国持有导云资产9 ...

Group 1 - The core opinion of the article is that the recent increase in shareholding by Guofang Group will result in a change of control for Suzhou Bank, making Guofang Group the controlling shareholder and the Suzhou Municipal Finance Bureau the actual controller [1][9] - Guofang Group has increased its shareholding in Suzhou Bank from 9.00% in 2009 to 15.00% after recent transactions, indicating a significant accumulation of shares [2][3] - The shareholding structure shows that Guofang Group holds 666,849,324 shares, representing 14.92% of the total share capital, while combined with its concerted action partner Dongwu Securities, they hold 15.00% [6][7] Group 2 - Prior to this change, Suzhou Bank did not have a controlling shareholder or actual controller since its IPO in 2019 [5][6] - The analysis indicates that Guofang Group's shareholding is significantly higher than that of other shareholders, which allows it to exert substantial influence over shareholder meetings and board decisions [7][8] - The board of directors of Suzhou Bank consists of 13 members, with Guofang Group managing or nominating a majority of the non-independent directors, further solidifying its influence [8][9]